• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery

    Injectable Drug Delivery Trends

    Oral Solids: Market & Technology Trends
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Cytovance Biologics

    Emergent BioSolutions

    Syngene

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Aphena Pharma Solutions

    Emergent BioSolutions

    Reed-Lane

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    How to Balance Internal and External Staff Within Outsourcing Models

    Strategies to consider in flexed staffing models.

    How to Balance Internal and External Staff Within Outsourcing Models
    Related CONTENT
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm
    • QTS Medical Device Outsourcing
    • Pii Gets Registered as a Part of the FDA’s 503B Solution
    • Advanced Analytical Features Services
    John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD09.22.20
    Today, many pharma and biotech companies are moving away from the traditional “all in” and “all out” staffing models where roles were either fully outsourced or sourced entirely from the company’s internal capabilities. Traditional “all in” models create the risk of stranded or under-utilized resources. An “all out” model solves that problem, but at the expense of losing the internal competence of the role.

    To solve for these challenges, many companies are turning to flexed staffing models which maintain some of the internal competence for a role while avoiding the risk of overstaffing internally. A flexed staffing model is one where the resources to satisfy a particular role competence are provided by a blend of customer and supplier resources. For example, 30% of the clinical research associate (CRA) roles at an organization might be staffed by internal employees, while the remaining 70% are supplier-based (non-employee) resources. This ultimately results in a lower cost to deliver the portfolio delivery while at the same time minimizing and mitigating possible co-employment risks.  

    One question still remains: What is the right level of internal and external staff?

    Consider the flex ratio.

    What is a flex ratio?
    Historically, pharma companies that went through operating model transformations often considered a role as either 100% internally staffed or 100% outsourced. This was done as a way to create a more flexible workforce and to ensure the co-employment risk was well-managed.

    This strategy presents a unique challenge for the customer as they lose all internal access to the particular role that has been outsourced. Because of this, we’ve recently seen companies change their strategy and begin rebuilding some internal capabilities. Now, many companies have a mixed model approach, with a portion of their workforce sourced as employees and the remainder sourced by suppliers. That’s where the flex ratio comes into play.

    The flex ratio is simply the proportion of external staff as a percentage of the total. For example, a flex ratio of 80% means that eight out of ten staff are sourced externally and only two are actual customer employees. A variable flex ratio attempts to formulaically determine the right level of internal and external staff for each particular sponsor. Each role is assigned a variable flex ratio based on the key criteria below. The flex ratio percentage determines the percent of staff out (outsourced from a CRO) or in (employees). This moves the sponsor from a staff augmentation model to a resource management model and begins to include some provisioning of infrastructure support from the supplier.

    What is the right level of internal and external staff?
    Based on five general principles, we can derive a flex ratio for any role under consideration:

    •    Knowledge Investment
    It’s important to measure the knowledge-based investment made by a company into a resource. These investments include things like training, continuing education, and leadership development, and can be quite expensive. If an employee leaves or is reassigned, knowledge investments made by the sponsor become a sunk cost to the company. The higher this investment, the more likely the company will want to retain the staff, which is easier to control when they are employees. On the contrary, highly administrative roles that require less knowledge investment will have a higher flex ratio and therefore be outsourced more frequently than roles that require a significantly higher knowledge investment.

    Bottom line: The higher the knowledge investment, the lower the flex ratio.

    •    Scale
    When determining a flex ratio, we must also consider the total number of resources required, or the scale. Scale affects the flex ratio for two main reasons. The larger the scale, the more likely that the competence itself is not a core competence or is not difficult to access externally. A large workforce of employees does not necessarily create a competitive advantage.

    More importantly, the higher the scale, the higher the risk of stranded resources if the development portfolio reduces or shifts its geographic focus. Many decision-makers ask, “What happens when the company grows?” However, they often neglect to address what happens when the company doesn’t.

    Bottom line: The larger the scale, the higher the flex ratio.

    •    Duration to Available
    How long it takes for a resource to be made available is another factor to consider in a highly competitive resource market. For example, securing a CRA may take less time than finding an MD—this time is an investment. The longer it takes to find someone to fill a role, the more likely it is that the organization will want to protect that investment. That’s easier to do with an employee than it is to “rent” that competence from a supplier.

    Bottom line: The longer it takes to find and secure an employee, the lower the flex ratio.

    •    Knowledge Dependence
    It’s also critical to measure the difference between tacit and explicit knowledge. Generally, people have tacit knowledge. This is what drives relationships. The more a role’s effectiveness depends on managing a relationship, the lower the flex ratio. Likewise, explicit knowledge is in the process of the system, not necessarily the people. For process-driven roles such as many found in data management, it’s possible to change staff members without losing process knowledge. Therefore, explicit knowledge dependence equates to a much higher flex ratio.

    Bottom line: The more tacit knowledge is required for a role, the lower the flex ratio. The more the role will depend on explicit knowledge, the higher the flex ratio.

    •    Competitive Advantage
    Does “owning” the resource create a competitive advantage for the company? For example, an organization would likely prefer to have a pioneering scientist who discovers a new immunotherapy candidate as an employee so that they could protect this knowledge capital. The same might be said for a thought leader whose name and expertise a company wants to be associated with.

    Bottom line: The higher the competitive advantage, the lower the flex ratio.

    So, how exactly does the flex formula work?
    To determine the “right” flex ratio for a sponsor, the above considerations can be weighted and scored based on the sponsor’s priorities. As the role-based flex ratio is determined, it’s important to balance the competing risks. A higher flex ratio may increase risk related to ownership and accountability, higher turnover, and the loss of a functional role as a core competence. On the other hand, a lower flex ratio may increase risk related to stranded resources, performance management, access to the appropriate resource, and portfolio ebbs and flows.

    Flex Ratio Criteria Table: The Flex Formula1


    Applying the Formula
    When we use a Likert scale (or similar) and apply the formula, the above example yields the following flex ratio results:


     

     
    We find the benefits of these flexed models usually outweigh the risks. The variable flex ratio allows you to manage co-employment risks, stranded resource risk, and maximize returns on people investments. Unlike the traditional “all in” and “all out” staffing models which strike an imbalance in risk management, the flexed model manages these risks more effectively. Working with an experienced CRO that embeds its own staff within your functional portfolio can help you to assess, manage, and mitigate many co-employment risks that may exist within traditional staffing approaches.



    John Barry serves as the SVP and Chief Strategy Officer for PRA’s Strategic Solutions Division. In this role, John is responsible for managing the division’s consulting practice and providing strategic oversight on key opportunities and customer models. John has extensive experience in the drug development industry and has worked as an executive leader in a variety of functions including alliance management, business development, clinical operations, contracts, proposals, and legal. Prior to joining PRA, John was the COO at a mid-size CRO, after 4 years as head of portfolio sourcing and relationship management and a member of the senior leadership team for Merck Research Laboratories’ Global Clinical Trials Organization. Prior to joining Merck, John spent over 20 years working for two of the top five global CROs.
    Related Searches
    • Drug Development
    • Clinical Trials
    Suggested For You
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm
    QTS Medical Device Outsourcing QTS Medical Device Outsourcing
    Pii Gets Registered as a Part of the FDA’s 503B Solution Pii Gets Registered as a Part of the FDA’s 503B Solution
    Advanced Analytical Features Services Advanced Analytical Features Services
    Federal Equipment Federal Equipment's Adam Covitt
    JML Consulting Group JML Consulting Group

    Related Expert's Opinion

    • Clinical Trials | Information Technology
      Top 5 Things to Know Before Selecting Clinical Trial Technology

      Top 5 Things to Know Before Selecting Clinical Trial Technology

      Look for a future-proof model, innovative vendors - not cutting-edge technology, and focus on user-centered design and interoperability.
      Andres Garcia, Co-founder and CTO Florence 02.08.21

    • Clinical Trials
      The Future of Clinical Trials Series: Part II

      The Future of Clinical Trials Series: Part II

      Greater awareness will ensure diversity is no longer an afterthought and patients will be at the center of every aspect of clinical research.
      Jena Daniels, Rasmus Hogreffe, Ingrid Oakley-Girvan, Dr. Michelle Longmire, Medable 01.26.21

    • Clinical Trials
      The Future of Clinical Trials Series: Part I

      The Future of Clinical Trials Series: Part I

      What will 2021 have in store for an industry in flux?
      Alison Holland, Head of Decentralized Trials, Medable, Maria Fotiu, Executive Vice President of Decentralized Solutions, Syneos Health 01.19.21


    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21

    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21


    • Clinical Trials | Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown, SVP of Integrated Technology & Compliance, and Joe Rymsza, VP, Global PV & Regulatory Technology Solutions, IQVIA 12.14.20

    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20

    • Drug Development
      Navigating Uncertainty: Considerations for Life Sciences 2021

      Navigating Uncertainty: Considerations for Life Sciences 2021

      With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.
      Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP 12.11.20


    • Clinical Trials | Information Technology
      AI and Advanced Analytics

      AI and Advanced Analytics

      Equipped with the right tools, CROs are better positioned to develop optimal protocols, rapidly identify patients to enroll, and preempt study issues.
      Paul Oliver, Medidata 11.13.20

    • Clinical Trials | Information Technology
      eCOA: Addressing Barriers to Faster Deployment in Clinical Trials

      eCOA: Addressing Barriers to Faster Deployment in Clinical Trials

      Clinical Outcome Assessments are an increasingly important tool in clinical research.
      Paul O'Donohoe, Scientific Lead, eCOA and Mobile Health, Medidata 11.13.20

    • Clinical Trials | Information Technology
      Adding Remote Site Access to Sponsor Bids: What to Know as CRO

      Adding Remote Site Access to Sponsor Bids: What to Know as CRO

      Traditional monitoring has changed, CROs should build a portfolio of remote access solutions and have them ready.
      Ryan Jones, CEO, Florence Healthcare 10.13.20


    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20

    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • WuXi AppTec Completes OXGENE Acquisition
    • Arcline Investment Acquires ChargePoint Technology
    Breaking News
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    • Four Female Leaders Appointed to Cell & Gene CDMO
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Study Explains Link Between Probiotic Strains and Children’s Immune Health Benefits
    Maypro Launches Brain Heatlh Ingredient NeuroHD
    Gadot Biochemical Launches New Magnesium Ingredients
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Benjamin Moore Launches COMMAND
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Ready Robotics Hires Proven Automation Leaders
    Philips, Disney Join Forces to Reduce Childrens' MRI Anxiety
    FDA OKs Asensus' Senhance for General Surgery
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Innoforce and dMed Enter Development Collaboration
    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    Four Female Leaders Appointed to Cell & Gene CDMO
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    BizBash Names Unfiltered Experience ‘People's Choice: Best Influencer Event’
    P&G Makes Progress Toward Packaging Circularity in Europe
    Coty Partners with LanzaTech to Introduce Sustainable Ethanol
    Happi

    Latest Breaking News From Happi

    Uoma Beauty Unveils a 'Coming 2 America' Makeup Collaboration
    Coty Partners with LanzaTech to Reduce Its Environmental Impact
    Waterless Beauty, Simplified Routines Shape Clean Beauty at Whole Foods
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Fort Dearborn Company acquires Hammer Packaging
    Ashland announces PSA price hike in North America
    Arrow Systems and Sihl form flexible packaging partnership
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Joa Announces Expandable Absorbent Core Wrap Solution
    Principle Business Enterprises Celebrates 60 Years
    Mann+Hummel Invests in Pamlico Air
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Lincotek Medical Expands Coatings and Additive Capacity
    Spinal Elements Relaunches the Luna XD and Orbit Systems
    Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login